Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Proprietary cell lines offer opportunities for achieving high AAV titers.

Proprietary Cell-Line Development for High-Titer AAV Manufacturing

In the ATMP space, CGTs are hitting their stride with unprecedented approvals in the past year alone.

Bracing for a Future Wave of Advanced Therapies

Topic

Feliza Mirasol is the science editor for 

Articles

The Novo Nordisk Foundation has committed DKK 600 million (US$87.4 million) towards the initial costs of the center housing the new supercomputer, which has the potential to accelerate drug discovery innovation.

Novo Nordisk Foundation Announces Start Up of Denmark’s First AI Supercomputer Geared to Accelerate Drug Discovery Innovation

The collaboration aims to develop precision genetic medicines using ViaNautis’ proprietary polyNaut technology platform.

Lilly Forms Strategic Collaboration with ViaNautis Bio to Develop Novel Genetic Cargo-based Therapeutics

The company is investing $76 million to increase ADC manufacturing capacity at its St. Louis, Mo. facility.

MilliporeSigma to Expand ADC Manufacturing for Cancer Therapies

The companies expect to accelerate the clinical development of MRT-6160, a Phase I drug candidate, as well as explore further therapeutic opportunities across multiple indications.

Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics

Merck is acquiring the Yale-spinout, which develops direct DNA modification-enabled cancer treatments. 

Modifi Biosciences Acquired by Merck

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The Cambridge-GSK Translational Immunology Collaboration builds on an existing scientific relationship between the biopharma company and the university, with the aim of improving outcomes for patients.

Cambridge, GSK to Partner on R&D for Kidney and Respiratory Diseases

Videos

At AAPS PharmSci 360.Bala Addepalli, PhD, Director, R&D New Modalities Portfolio, Waters Corporation, discussed trends in new analytical tools for RNA characterization and gave highlights from his presentation.

Discussing Trends in New Analtyical Tools for RNA (AAPS PharmSci 360)

Karunakar Sukuru, RPh, PhD, the global vice-president-Rx Product Development, Pharma and Consumer Health, at Catalent Pharma Solutions, discussed lipid-based formulations and tackling bioavailability challenges for oral biologics at AAPS PharmSci 360.

The Need for LBFs and Challenges in Oral Biologic Formulation (AAPS PharmSci 360)

Chris Spivey is the editorial director of 

Cell and gene therapy experts Fabian Gerlinghaus, Dr. Claudia Zylberberg, and Benjamin McLeod weigh in on hot topics in CGT. 